Viracoat, which offers personal protective equipment that begins killing Covid-19 and other viruses on contact, has raised £2million to fund final stages of accreditation and further UK-based research.
The funding comes from J.J. Richards & Sons, an Australian family-owned and operated business that provides waste management service solutions throughout Australia and New Zealand and owns In Vitro Technologies, a scientific and medical distribution subsidiary.
The new PPE product is undergoing final stages of accreditation testing in the biomedical facilities at Lancaster University.
Dr Muhammad Munir, a virologist at Lancaster University said: “We are testing to be effective against SARS-CoV-2 variants first identified in UK (alpha), South Africa (beta), Brazil (gamma) and India (delta) and also testing for efficacy against influenza and potentially other viruses.”
The product is planned be in production at scale by August through The MEL Group based in Sudbury, Suffolk. International sales and distribution, which are prioritising hospital and healthcare workers, have been contracted and international pre-production orders are being processed.
Viracorp chief executive, Jon Chadwick said: “This funding is important to completing the accreditation process for this breakthrough product and to enable continued research into its application against Covid-19, its variants and other viruses. Viruses such as the Coronavirus need to be neutralised, not just blocked, to reduce the risk of transmission through the air or by contact to keep frontline workers and patients safe.”
Jennifer Parsons, director at In Vitro Technologies added: “We are very excited to be part of the delivery to market of these innovative new products which could potentially turn the tide on Covid-19 pandemic and protect us from other deadly viruses as well. We look forward to bringing this state-of-the-art viricidal PPE to our customers in Australia and New Zealand.”
Date published: July 5, 2021